CLASS ACTION UPDATE for COIN, SESN and HYRE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / September 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

COIN Shareholders Click Here: https://www.zlk.com/pslra-1/coinbase-global-inc-loss-submission-form?prid=19507&wire=1
SESN Shareholders Click Here: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=19507&wire=1
HYRE Shareholders Click Here: https://www.zlk.com/pslra-1/hyrecar-inc-loss-submission-form?prid=19507&wire=1

* ADDITIONAL INFORMATION BELOW *

Coinbase Global, Inc. (NASDAQ:COIN)

This lawsuit is on behalf of all persons and entities that purchased or otherwise acquired Coinbase Class A common stock pursuant and/or traceable to the Company's registration statement and prospectus for the resale of up to 114,850,769 shares of its Class A common stock, whereby Coinbase began trading as a public company on or around April 14, 2021.
Lead Plaintiff Deadline : September 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/coinbase-global-inc-loss-submission-form?prid=19507&wire=1

According to the filed complaint, (1) the Company required a sizeable cash injection; (2) the Company's platform was susceptible to service-level disruptions, which were increasingly likely to occur as the Company scaled its services to a larger user base; and (3) as a result of the foregoing Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Sesen Bio, Inc. (NASDAQ:SESN)

SESN Lawsuit on behalf of: investors who purchased December 21, 2020 - August 17, 2021
Lead Plaintiff Deadline : October 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=19507&wire=1

According to the filed complaint, during the class period, Sesen Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

HyreCar Inc. (NASDAQ:HYRE)

HYRE Lawsuit on behalf of: investors who purchased May 14, 2021 - August 10, 2021
Lead Plaintiff Deadline : October 26, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/hyrecar-inc-loss-submission-form?prid=19507&wire=1

According to the filed complaint, during the class period, HyreCar Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) HyreCar had materially understated its insurance reserves; (b) HyreCar had systematically failed to pay valid insurance claims incurred prior to the Class Period; (c) HyreCar had incurred significant expenses transitioning to its new third-party insurance claims administrator and processing claims incurred from prior periods; (d) HyreCar had failed to appropriately price risk in its insurance products and was experiencing elevated claims incidence as a result; (e) HyreCar had been forced to dramatically reform its claims underwriting, policies and procedures in response to unacceptably high claims severity and customer complaints; and (f) as a result, HyreCar's operations and prospects were misrepresented because the Company was not on track to meet the financial estimates provided to investors during the Class Period, and such estimates lacked a reasonable basis in fact, including HyreCar's purported gross margin, EBITDA (earnings before interest, taxes, depreciation, and amortization), and net loss trajectories.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP